Sickle Cell Disease (SCD) Treatment in Turkey
- Top Accredited Hospitals
- Global Medical Standards
- Cutting-Edge Technology
- Proven Treatment Options
- High Success Rate
- Trusted by Millions
What is a Sickle Cell Disease (SCD)?
Sickle cell disease (SCD) is a group of inherited blood disorders caused by abnormal haemoglobin, most commonly haemoglobin S. This abnormal haemoglobin can make red blood cells rigid and sickle-shaped, making them more likely to break down early and block small blood vessels. This can lead to anaemia, painful vaso-occlusive crises and progressive damage to organs such as the lungs, kidneys, brain, bones and spleen. SCD is inherited when a child receives disease-causing haemoglobin variants from their parents.
What is the Importance of Timely Treatment?
Timely diagnosis and comprehensive treatment can help reduce painful crises, prevent complications and protect organ function. Regular monitoring allows doctors to identify anaemia, infection, stroke risk, kidney problems, eye complications and other effects of SCD at an earlier stage. Disease-modifying medicines, transfusion programmes, vaccination and preventive care can reduce complications, while selected patients with severe disease may be evaluated for hematopoietic stem-cell transplantation or gene therapy.
What are the Common Symptoms of Sickle Cell Disease (SCD)?
- Episodes of severe pain, known as vaso-occlusive crises
- Chronic or recurrent anaemia
- Fatigue and weakness
- Shortness of breath
- Pale skin or yellowing of the eyes
- Swelling of the hands and feet, particularly in young children
- Frequent infections
- Delayed growth or puberty in some children
- Bone and joint pain
- Abdominal pain
- Vision problems
- Symptoms related to stroke or neurological complications
- Priapism in some males
- Chronic organ-related complications in severe disease
Causes and Risk Factors of Sickle Cell Disease (SCD)
Causes
- Sickle cell disease results from inherited changes in the HBB gene, which provides instructions for producing beta-globin, a component of haemoglobin.
- Different combinations of abnormal haemoglobin genes can produce different forms of SCD.
- The most severe and common form, HbSS, generally occurs when a child inherits a sickle haemoglobin gene from both parents.
Risk Factors
- Having parents who carry sickle haemoglobin or another disease-causing haemoglobin variant
- Family history of sickle cell disease
- Inheriting two disease-causing haemoglobin variants
- Genetic ancestry associated with a higher prevalence of sickle haemoglobin, including parts of Africa, the Middle East, the Mediterranean, South Asia and other regions
- Lack of access to early screening and comprehensive SCD care, which can increase the risk of preventable complications
Latest Research and Technologies in the Treatment of Sickle Cell Disease (SCD) in Turkey
- Sickle cell treatment is increasingly moving toward disease-modifying and potentially curative approaches. Hydroxyurea remains an important therapy to reduce sickling and complications, while blood transfusion programmes are used in selected patients. Hematopoietic stem-cell transplantation can provide a potential cure for appropriately selected patients, particularly those with severe disease and a suitable donor. Gene therapies have introduced another potential curative approach. These therapies require specialised cell collection, conditioning treatment and long-term monitoring and are currently intended for carefully selected patients.
Treatment options for Sickle Cell Disease (SCD)
Blood Transfusion Therapy: Red blood-cell transfusions may treat severe anaemia or prevent or manage selected complications, such as stroke. Long-term transfusion programmes require monitoring for iron overload and other transfusion-related complications.
Stem-Cell Transplantation : Allogeneic hematopoietic stem-cell transplantation can potentially cure SCD in selected patients. Suitability depends on factors such as disease severity, organ health, age, donor availability and the risks associated with transplantation.
Cost Start From 20000Explore Options
Gene Therapy: Selected patients with severe SCD may be evaluated for autologous gene-based therapies. These approaches involve collecting the patient's own blood-forming stem cells, modifying them in a specialised laboratory and returning them after conditioning treatment.
- Clinical assessment:
- Medical and Haematological Evaluation: A detailed history is taken to assess pain crises, fatigue, anemia, infections, transfusion history, jaundice, breathing problems, neurological symptoms, vision changes, bone complications and other SCD-related symptoms.
- Complete Blood Count and Peripheral Blood Assessment: A complete blood count evaluates hemoglobin, red blood cells, white blood cells, and platelets. A peripheral blood smear can show red-cell morphology and other blood abnormalities associated with SCD.
- Hemoglobin Analysis: Hemoglobin electrophoresis, high-performance liquid chromatography or other specialised testing can identify abnormal hemoglobin types and help determine the specific SCD genotype or hemoglobinopathy.
- Assessment of Organ Complications: Depending on age and symptoms, evaluation may include kidney function and urine testing, liver assessment, pulmonary evaluation, eye examination and neurological assessment.
- Genetic and Family Assessment: Genetic counselling and testing may help clarify the inherited hemoglobin pattern and provide information about reproductive risks and family screening.
- Imaging Tests:
- Transcranial Doppler Ultrasound: Used particularly in children with SCD to assess cerebral blood-flow velocities and help identify increased stroke risk.
- Brain MRI and MRA: May be recommended when neurological symptoms, previous stroke or silent cerebral injury is suspected.
- Chest X-ray: May be used when acute chest syndrome, pneumonia or another chest complication is suspected.
- Echocardiography: May be used to evaluate cardiac structure and function when clinically indicated.
- Ultrasound or MRI: May help evaluate abdominal, bone, or other organ complications depending on symptoms.
- Retinal Imaging: Ophthalmologic imaging can detect sickle-cell-related retinal changes.
MediRehab (a chain of Rehab centres, part of MediGence) provides comprehensive tele-rehabilitation services designed to support Sickle Cell Disease (SCD) patients in Turkey. These services include:
- Physical Activity and Exercise: Individualised physical activity can help maintain strength, mobility and cardiovascular fitness, with intensity adjusted according to anemia, pain, organ complications and overall health.
- Pain and Mobility Rehabilitation: Physiotherapy may help patients manage chronic musculoskeletal pain, maintain joint mobility and improve functional movement while avoiding activities that worsen symptoms.
- Fatigue and Energy Management: Structured activity planning, appropriate rest, sleep support and treatment of underlying anemia can help patients manage chronic fatigue and maintain daily activities.
- Psychological and Self-Management Support: Counselling, patient education and chronic-pain support can help patients cope with recurrent crises, treatment demands, school or work limitations and the emotional effects of living with a chronic blood disorder.
- Medicines for SCD aim to reduce sickling, prevent complications and manage acute symptoms. Hydroxyurea is an established disease-modifying medicine that can increase fetal hemoglobin and reduce the frequency of pain crises in appropriate patients. Other medicines may be used for pain management and selected disease-related complications. Pain-relief medicines are used during crises, while patients receiving repeated transfusions may need monitoring and treatment for iron overload. Regular follow-up helps assess treatment response and identify adverse effects.
Instantly Connect with our Specialists
Hospitals for Sickle Cell Disease (SCD) in Turkey
Medstar Antalya Hospital
Ankara, Turkey
- Medstar Antalya Hospital has been providing patients with modern medical services since 2009.
- It is part of the trusted Memorial Health Group, which is known for expert healthcare in Turkey.
- The hospital is situated on a large campus and features advanced medical equipment and facilities.
- It has 124 comfortable beds for patients and five fully prepared operating rooms for surgeries.
- There are 33 intensive care beds, including specialised units for newborns who require additional support.
- The hospital treats many health issues like cancer, heart problems, brain conditions, and more.
- Modern machines, such as MRI, CT, and PET-CT, help doctors identify and treat problems quickly and safely.
- Medstar meets international safety and care standards and is trusted by both local and global patients.
- Care plans are made specially for each person, and emotional well-being is also supported.
- Its location in Antalya makes it easy to reach and ideal for people coming from other countries for treatment.
Guven Hospital
Ankara, Turkey
Started as a small hospital and has become a large general Hospital with-
- 254 beds
- 12 Operating rooms
- Staff of 1600 people including expert physicians, nurses, and auxiliary health personnel
- Guven Medical Surgical Centre
- IVF Centre
- Blood Bank
- Organ Transplant Centre
- Fully-equipped centres to perform various types of Surgeries
- Guven Healthy Living Campus for patients
Our Services to better your experience
Opinion & Option
We submit the most accurate opinion and options from one or more countries for your review
Consult Privately
Consult with a certified specialist privately on our telemedicine platform even before you decide to travel
Logistics
We handle flights, visas, transfers, and accommodation—so you can focus on your health.
Recovery
Our In-house rehabilitation service packages to better your recovery and treatment outcome
Why Choose Turkey for Sickle Cell Disease (SCD) Treatment?
- Multidisciplinary Hematology Care: Patients can access hematologists, pediatric hematologists, transfusion specialists, genetic counsellors and other specialists according to their needs.
- Advanced Diagnostic Facilities: Specialised centres may provide hemoglobin analysis, genetic testing, blood-count monitoring, organ-function assessment and imaging for SCD-related complications.
- Comprehensive Disease Management: Treatment can include hydroxyurea, pain management, transfusion programmes, vaccination and monitoring for organ complications.
- Stem-Cell Transplantation: Major transplant centres can evaluate eligible patients for allogeneic hematopoietic stem-cell transplantation and provide donor assessment and post-transplant monitoring.
- Advanced Cellular and Gene-Based Therapies: Specialised centres may provide access to emerging cellular or gene-based treatment programmes where regulatory approval, clinical eligibility and infrastructure permit.
Frequently Asked Questions
Sickle cell disease is a lifelong inherited condition, not an illness with a fixed recovery period. Individual pain crises may resolve over hours or days with appropriate treatment, while chronic complications require ongoing management. Some patients undergoing stem-cell transplantation or gene therapy may require prolonged treatment and recovery.
Yes. Most people with SCD can walk and remain physically active. However, severe anemia, pain, bone or joint complications and other health problems may affect mobility. Adjust physical activity based on symptoms and guidance from the treating healthcare team.
Specialist centres in Turkey may offer hemoglobin analysis, genetic testing, transfusion services, stroke-risk screening and monitoring for organ complications. Some centres may also provide hematopoietic stem-cell transplantation. Access to advanced gene therapies depends on local regulatory approval, treatment availability, and patient eligibility, so confirm this with the hospital.
Many major Turkish hospitals have international-patient departments that can assist with medical records, specialist consultations, treatment coordination, travel arrangements, accommodation and follow-up care.
Consider a centre with experienced hematologists and access to comprehensive SCD care, including blood transfusion services, genetic testing, management of acute and chronic complications and multidisciplinary support. If you are considering curative treatment, evaluate the centre's experience with hematopoietic stem-cell transplantation and access to appropriate specialised therapies.
Treatment outcomes depend on the patient's age, disease severity, frequency of complications, organ health and the type of treatment received. Disease-modifying treatment can reduce painful crises and other complications, while stem-cell transplantation and certain gene therapies may offer potentially curative options for selected patients. A specialist can explain the expected benefits and risks based on the patient's medical history and eligibility.
Hematologists and pediatric hematologists at specialised Turkey centres manage SCD, including pain crises, anemia, transfusion requirements, stroke prevention, organ complications and disease-modifying treatment. Patients considering transplantation or advanced cellular therapies should consider centres with relevant specialist experience.
Treatment risks depend on the therapy used. Hydroxyurea and other medicines can cause treatment-specific adverse effects and require monitoring. Blood transfusions can cause reactions, alloimmunisation and iron overload. Stem-cell transplantation carries risks including infections, graft-versus-host disease and other transplant-related complications. Gene therapies require intensive conditioning and specialised cell-based treatment and may also carry serious risks that require long-term monitoring.
Sickle cell disease is an inherited blood disorder, not an injury. Seek prompt medical assessment for a new or severe pain crisis. Fever, chest pain, difficulty breathing, sudden weakness, confusion, severe headache or changes in vision require urgent medical attention, as these may indicate serious complications.
SCD does not typically cause structural deformities by itself, but repeated vaso-occlusive events and chronic anemia can contribute to bone and joint damage, growth problems and other long-term complications. Early, comprehensive management can reduce the risk of preventable complications.
Yes. Recurrent pain crises, fatigue, hospital visits, anemia, treatment requirements and chronic organ complications can affect physical activity, education, employment, sleep and emotional well-being. Comprehensive disease management and appropriate psychosocial support can help patients maintain independence and daily functioning.
Yes. Untreated or inadequately managed SCD can cause recurrent pain crises and progressive complications affecting the brain, lungs, kidneys, eyes, bones, heart and other organs. Severe complications can include stroke, acute chest syndrome, severe anemia, infections and chronic organ damage.
SCD is an inherited genetic condition and cannot be prevented after a person inherits the disease-causing variants. However, carrier screening and genetic counselling can help individuals and couples understand their reproductive risks. For people living with SCD, preventive healthcare, vaccinations, prescribed medicines, regular monitoring and avoidance of known triggers can help reduce complications.
SCD is more common in populations with ancestry from regions where the sickle hemoglobin gene is more prevalent, including parts of Africa, the Middle East, the Mediterranean and South Asia. In Turkey, sickle cell disease is particularly relevant in several tribal and other communities. Because SCD is inherited, having parents who carry disease-causing hemoglobin variants increases the likelihood of inheriting the condition.
Reviewer
Dr. Akash Khandelwal
Hematologist
9 Years of Experience
Dr. Akash Khandelwal is a distinguished Hematologist, Hemato-oncologist, and Bone Marrow Transplant (BMT) Physician with extensive training from the prestigious AIIMS New Delhi. His expertise encompasses a wide range of specialized techniques in bone marrow transplantation, including autologous and allogeneic transplants such as matched sibling donors, matched unrelated donors (MUD), and haploidentical donor transplants. Dr. Khandelwal has personally supervised and conducted over 100 bone marrow transplants. View More
Last Reviewed - January 2026